Mattias Sandström

Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing ¹⁷⁷Lu-DOTA-Octreotate Treatment

Mattias Sandström, Ulrike Garske‐Román, Silvia Johansson et al. · Journal of Nuclear Medicine · 2012 · 275 citations · Full text

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸Ga]ABY-025 Affibody PET/CT

Jens Nørkær Sørensen, Irina Velikyan, Dan Sandberg et al. · Theranostics · 2015 · 260 citations · Full text

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the ¹¹¹In-ABY-025 Affibody Molecule

Jens Sørensen, Dan Sandberg, Mattias Sandström et al. · Journal of Nuclear Medicine · 2014 · 257 citations · Full text

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Ulrike Garske‐Román, Mattias Sandström, Katarzyna Fröss Baron et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 240 citations · Full text

Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule

Vladimir Tolmachev, Anna Orlova, Rikard Pehrson et al. · Cancer Research · 2007 · 217 citations